Business
Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE IDE trial and its AMDS PERSEVERE IDE trial at the 62nd Annual Meeting of the Society of Thoracic Surgeons in New Orleans, Louisiana.
About this update from Artivion, Inc.
[{"type":"text","content":"1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity","length":109,"tagName":"p","attribs":{}},{"type":"text","content":"2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical Benefit of AMDS","length":105,"tagName":"p","attribs":{}},{"type":"text","content":"ATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE IDE trial and its AMDS PERSEVERE IDE trial at the 62nd Annual Meeting of the Society of Thoracic Surgeons in New Orleans, Louisiana.","length":382,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Artivion, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Artivion, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":57,"url":"https://media.zenfs.com/en/prnewswire.com/9c706ade2059beb91e5927de844091ef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IDclkFr3MoZKf5vK0cCAAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9c706ade2059beb91e5927de844091ef","width":400,"height":57}},"href":"https://mma.prnewswire.com/media/1728034/Artivion_new_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The NEXUS TRIOMPHE IDE trial presentation of 94 patients highlighted 94% patient survival from lesion related death and 91% freedom from disabling stroke at 1-year post-treatment in this high-risk patient group. The data also showed 97% of patients were free from reintervention due to endoleaks with no occurrence of renal failure and one occurrence of paraplegia out to 1-year post-implant. Meanwhile, data from the AMDS PERSEVERE IDE trial demonstrated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry (DANE) tears between 1- and 2-year follow-up.","length":586,"tagName":"p"},{"type":"text","content":""We are pleased with the 1-year outcomes from the NEXUS TRIOMPHE trial and continued positive results from the AMDS PERSEVERE trial which further validate these important therapeutic options for patients with aortic arch disease," said Pat Mackin, Chairman, President, and Chief Executive...